WA
BPMC

WPG Advisers’s Blueprint Medicines BPMC Stock Holding History

WPG Advisers’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-45
Closed -$5.77K – 1454
2025
Q2 		$5.77K Buy
45
+6
+15% +$623 ﹤0.01% 835
2025
Q1 		$3.45K Buy
39
+7
+22% +$683 ﹤0.01% 984
2024
Q4 		$2.79K Buy
+32
New +$2.93K ﹤0.01% 1001

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

WPG Advisers's BPMC Position: Q3 2025 in Review

WPG Advisers sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 45 shares — an estimated $5.77K sold.

WPG Advisers first reported a position in BPMC in Q4 2024 and held it in 3 quarters. The position peaked at $5.77K in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • WPG Advisers reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • WPG Advisers sold 45 Blueprint Medicines shares in Q3 2025, an estimated $5.77K.
  • WPG Advisers first reported a position in Blueprint Medicines in Q4 2024 and held it in 3 quarters.
  • WPG Advisers's Blueprint Medicines position peaked at $5.77K in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on WPG Advisers's 13F filing for Q3 2025, filed 29 Oct 2025.